Li Jinjian, Long Siyu, Liu Boyuan, Hong Shubin, Yu Shuang, Li Yanbing, Wu Dide, Xiao Haipeng
Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province 510080, China.
J Endocr Soc. 2025 Jun 23;9(9):bvaf108. doi: 10.1210/jendso/bvaf108. eCollection 2025 Sep.
Hypothyroidism's role in coronary heart disease (CHD) and its link with lipid metabolism is debated. Our study aims to clarify the causal relationship between hypothyroidism and CHD, focusing on the potential mediating effects of lipid profiles.
To assess the causal effect of hypothyroidism on the development of CHD and examine the mediating role of lipid profiles through Mendelian randomization (MR).
We conducted MR tests using genome-wide association study data of 500 000 participants of European ancestry from FinnGen and UK Biobank, respectively. Bidirectional MR tests were utilized to confirm causality, and the results of an inverse variance weighted method served as the main analysis. Weighted median, MR-Egger, and MR-Pleiotropy Residual Sum and Outlier methods were utilized as sensitivity analyses to validate our findings.
We found genetically predicted hypothyroidism increased the risk of CHD by 7.8% [odds ratio (OR) = 1.078, 95% confidence interval (CI) 1.026-1.134, = .003]. This liability was also inversely associated with high-density lipoprotein cholesterol (HDL-C) levels (β = -0.013, 95% CI -0.022-0.004, = .005) and apolipoprotein A-I levels (β = -0.014, 95% CI -0.025-0.004, = .008). HDL-C was inversely associated with coronary heart disease (OR 0.734, 95% CI 0.670-0.803, < .001), and apolipoprotein A-I was also inversely associated with coronary heart disease (OR 0.845, 95% CI 0.768-0.931, < .001).
Our findings suggested a causal link between hypothyroidism and increased CHD risk, likely mediated through changes in HDL-C and apolipoprotein A-I levels. This highlights the importance of monitoring lipid levels in hypothyroid patients and calls for further research to explore these relationships and their implications for prevention and treatment strategies.
甲状腺功能减退在冠心病(CHD)中的作用及其与脂质代谢的联系存在争议。我们的研究旨在阐明甲状腺功能减退与冠心病之间的因果关系,重点关注脂质谱的潜在中介作用。
评估甲状腺功能减退对冠心病发生发展的因果效应,并通过孟德尔随机化(MR)研究脂质谱的中介作用。
我们分别使用来自芬兰基因库(FinnGen)和英国生物银行(UK Biobank)的50万名欧洲血统参与者的全基因组关联研究数据进行MR检验。采用双向MR检验来确认因果关系,逆方差加权法的结果作为主要分析。加权中位数法、MR-Egger法和MR-多效性残差总和与离群值法用作敏感性分析以验证我们的发现。
我们发现基因预测的甲状腺功能减退使冠心病风险增加7.8%[比值比(OR)=1.078,95%置信区间(CI)1.026 - 1.134,P = 0.003]。这种易感性也与高密度脂蛋白胆固醇(HDL-C)水平呈负相关(β = -0.013,95% CI -0.022 - 0.004,P = 0.005)以及载脂蛋白A-I水平呈负相关(β = -0.014,95% CI -0.025 - 0.004,P = 0.008)。HDL-C与冠心病呈负相关(OR 0.734,95% CI 0.670 - 0.803,P < 0.001),载脂蛋白A-I也与冠心病呈负相关(OR 0.845,95% CI 0.768 - 0.931,P < 0.001)。
我们的研究结果表明甲状腺功能减退与冠心病风险增加之间存在因果联系,可能是通过HDL-C和载脂蛋白A-I水平的变化介导的。这突出了监测甲状腺功能减退患者脂质水平的重要性,并呼吁进一步研究以探索这些关系及其对预防和治疗策略的影响。